Development asset linked to EmeraMed in public FDA and regional records.
pharma · Hepatitis B, Chronic · Cancer
EmeraMed
Immunocore Ireland Limited
EmeraMed drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Ranelagh, IE HQ
2007 Founded
7 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Ranelagh, IE
- Founded
- 2007
- Employees
- 7
- Programs
- 5
- Drugs
- 9
- Patents
- 0
EmeraMed pipeline
Portfolio lens on 9 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
EmeraMed drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to EmeraMed in public FDA and regional records.
-
ipilimumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Cytotoxic T-lymphocyte protein 4.
- Target
- Cytotoxic T-lymphocyte protein 4
- Mechanism
- Cytotoxic T-lymphocyte protein 4 inhibitor
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement
-
Development asset linked to EmeraMed in public FDA and regional records.
-
tebentafusp
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in EmeraMed's portfolio. Molecular target: Melanocyte protein PMEL.
- Target
- Melanocyte protein PMEL
- Mechanism
- Melanocyte protein PMEL binding agent